Results 81 to 90 of about 75,630 (213)

Résistance médicamenteuse d'isolats récents de Trypanosoma brucei et Trypanosoma congolense

open access: yesRevue d’Elevage et de Médecine Vétérinaire des Pays Tropicaux, 1988
Des études ont été menées sur des souris pour déterminer la sensibilité aux médicaments d’isolats récents de Trypanosoma brucei et Trypanosoma congolense. Chacune des onze souches de T. congolense et des cinq souches de T. brucei, toutes isolées sur des
R.A. Joshua
doaj   +1 more source

Trypanosomal MICOS Is Assembled on Non‐Respiring Mitochondrial Crista Precursors and Associates With Two Integral Microproteins

open access: yesMolecular Microbiology, Volume 126, Issue 4, Page 396-411, October 2026.
The mitochondrial membrane‐shaping machinery MICOS is assembled surprisingly early during the life cycle of Trypanosoma brucei, before the mitochondrion acquires its mature architecture or full respiratory capacity. Our study also identifies two previously uncharacterized proteins associated with MICOS, providing new insight into the early organization
Michala Boudová   +5 more
wiley   +1 more source

TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei. [PDF]

open access: yes, 2014
The metabolic network of a cell represents the catabolic and anabolic reactions that interconvert small molecules (metabolites) through the activity of enzymes, transporters and non-catalyzed chemical reactions.
Opperdoes, F.R. (Fred)   +291 more
core   +2 more sources

Trypanosoma brucei

open access: yesTrends in Parasitology, 2020
Gabriela, Romero-Meza, Monica R, Mugnier
openaire   +4 more sources

Peptide‐Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives

open access: yesChemMedChem, Volume 21, Issue 18, 28 September 2026.
Peptide‐enabled nanoplatforms offer multifunctional strategies for the treatment and diagnosis of malaria and leishmaniasis. Liposomal, polymeric, and metallic nanocarriers, together with cell‐penetrating peptides and parasite‐derived mimotopes, can improve targeted drug delivery, stability, bioavailability, and intracellular localization.
Christian S. Carnero Canales   +7 more
wiley   +1 more source

Beyond the Active Site: First‐In‐Class Leishmania Infantum Trypanothione Reductase Dimerization Disruptors as Antileishmanial Leads

open access: yesChemMedChem, Volume 21, Issue 18, 28 September 2026.
This review outlines a pioneering strategy to inhibit Leishmania infantum trypanothione reductase by disrupting its dimer interface. From peptides to small‐molecule proteomimetics, multiple chemotypes achieved potent enzymatic inhibition and notable cellular antileishmanial activity, highlighting a new therapeutic paradigm.
María‐José Camarasa   +3 more
wiley   +1 more source

Identification and functional characterization of a highly divergent N-acetylglucosaminyltransferase I (TbGnTI) in Trypanosoma brucei [PDF]

open access: yes, 2014
Trypanosoma brucei expresses a diverse repertoire of N-glycans, ranging from oligomannose and paucimannose structures to exceptionally large complex N-glycans.
Damerow, Manuela   +5 more
core   +1 more source

Trypanosoma brucei infection protects mice against malaria.

open access: yesPLoS Pathogens, 2019
Sleeping sickness and malaria are parasitic diseases with overlapping geographical distributions in sub-Saharan Africa. We hypothesized that the immune response elicited by an infection with Trypanosoma brucei, the etiological agent of sleeping sickness,
Margarida Sanches-Vaz   +8 more
doaj   +1 more source

Trypanosoma Infection Favors Brucella Elimination via IL-12/IFNγ-Dependent Pathways

open access: yesFrontiers in Immunology, 2017
This study develops an original co-infection model in mice using Brucella melitensis, the most frequent cause of human brucellosis, and Trypanosoma brucei, the agent of African trypanosomiasis. Although the immunosuppressive effects of T.
Arnaud Machelart   +11 more
doaj   +1 more source

Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48

open access: yesInternational Journal for Parasitology: Drugs and Drug Resistance, 2018
The parasitic protozoan Trypanosoma brucei is the causative agent of human African trypanosomiasis (sleeping sickness) and nagana. Current drug therapies have limited efficacy, high toxicity and/or are continually hampered by the appearance of resistance.
Marta Martínez-García   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy